Literature DB >> 20096825

Recommendations for investigation of hyperandrogenism.

M Pugeat1, H Déchaud, V Raverot, A Denuzière, R Cohen, P Boudou.   

Abstract

1. Total testosterone assay is recommended as the first-line approach. 2. Radioimmunological assay following prior treatment of the sample (extraction or extraction + chromatography) is the recommended method pending wider experience with mass spectrometry. 3. Where testosterone is twice the upper limit of normal, it is recommended that DHEAS assay be performed. DHEAS is primarily of cortico-adrenal origin in women. Thus, a DHEAS level over 600 mg/dl indicates a diagnosis of androgen-secreting adrenal cortical adenoma.. If DHEAS is normal, the diagnosis could be either ovarian hyperthecosis, normally associated with insulin resistance, or androgen-secreting ovarian tumour. 4. More rarely, elevated testosterone is associated with a marked elevation of SHBG possibly as the result of use of medication having an estrogenic effect (tamoxifen, raloxifene, Op'DDD), or of hyperthyroidism or liver disease. 5. Normal testosterone levels in patients with clear clinical symptoms of hyperandrogenism (hirsutism, seborrhoeic acne) must be interpreted with care. SHBG is normally reduced in the event of overweight, metabolic syndrome or familial history of diabetes. Copyright (c) 2010. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096825     DOI: 10.1016/j.ando.2009.12.007

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  2 in total

1.  Postmenopausal hyperandrogenism due to an ovarian sex cord-stromal tumour causing elevated dehydroepiandrosterone sulphate: a case report.

Authors:  Manilka Sumanatilleke; Nipun Lakshitha de Silva; Gayani Ranaweera; Chinthaka Appuhamy; Kanishka Karunaratne; M V Chandu de Silva
Journal:  BMC Womens Health       Date:  2022-07-17       Impact factor: 2.742

2.  Steroidogenic enzyme profile in an androgen-secreting adrenocortical oncocytoma associated with hirsustism.

Authors:  Milène Tetsi Nomigni; Sophie Ouzounian; Alice Benoit; Jacqueline Vadrot; Frédérique Tissier; Sylvie Renouf; Hervé Lefebvre; Sophie Christin-Maitre; Estelle Louiset
Journal:  Endocr Connect       Date:  2015-06-01       Impact factor: 3.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.